Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
ALS
Alzheimer’s disease
Masitinib
Multiple sclerosis
Neurodegeneration
Neuroprotection
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
18 Dec 2023
18 Dec 2023
Historique:
received:
18
10
2023
accepted:
08
12
2023
medline:
18
12
2023
pubmed:
18
12
2023
entrez:
17
12
2023
Statut:
aheadofprint
Résumé
Masitinib, originally developed as a tyrosine kinase inhibitor for cancer treatment, has shown potential neuroprotective effects in various neurological disorders by modulating key pathways implicated in neurodegeneration. This scoping review aimed to summarize the current evidence of masitinib's neuroprotective activities from preclinical to clinical studies. This scoping review was conducted following the guidelines described by Arksey and O'Malley and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The inclusion criteria covered all original studies reporting on the neuroprotective effects of masitinib, including clinical studies, animal studies, and in vitro studies. A total of 16 studies met the inclusion criteria and were included in the review. These comprised five randomized controlled trials (RCTs), one post-hoc analysis study, one case report, and nine animal studies. The RCTs focused on Alzheimer's disease (two studies), multiple sclerosis (two studies), and amyotrophic lateral sclerosis (one study). Across all included studies, masitinib consistently demonstrated neuroprotective properties. However, the majority of RCTs reported concerns regarding the safety profile of masitinib. Preclinical studies revealed the neuroprotective mechanisms of masitinib, which include inhibition of certain kinases interfering with cell proliferation and survival, reduction of neuroinflammation, and exhibition of antioxidant activity. The current evidence suggests a promising therapeutic benefit of masitinib in neurodegenerative diseases. However, further research is necessary to validate and expand upon these findings, particularly regarding the precise mechanisms through which masitinib exerts its therapeutic effects. Future studies should also focus on addressing the safety concerns associated with masitinib use.
Identifiants
pubmed: 38105307
doi: 10.1007/s10072-023-07259-w
pii: 10.1007/s10072-023-07259-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Tang Y, Liang X, Han L et al (2020) Cognitive function and quality of life in Parkinson’s disease: a cross-sectional study. J Park Dis 10:1209–1216. https://doi.org/10.3233/JPD-202097
doi: 10.3233/JPD-202097
Arthur KC, Calvo A, Price TR et al (2016) Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun 7:1–6. https://doi.org/10.1038/ncomms12408
doi: 10.1038/ncomms12408
Heitmann RC (2012) Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2:a006239. https://doi.org/10.1101/cshperspect.a006239
doi: 10.1101/cshperspect.a006239
Clare L, Teale JC, Toms G et al (2019) Cognitive rehabilitation, self-management, psychotherapeutic and caregiver support interventions in progressive neurodegenerative conditions: a scoping review. NeuroRehabil 43:443–471. https://doi.org/10.3233/NRE-172353
doi: 10.3233/NRE-172353
Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Prim 3:17071. https://doi.org/10.1038/nrdp.2017.71
doi: 10.1038/nrdp.2017.71
pubmed: 28980624
Chen J, Wang T, An C et al (2016) Brain-derived neurotrophic factor: a mediator of inflammation-associated neurogenesis in Alzheimer’s disease. Rev Neurosci 27:793–811. https://doi.org/10.1515/revneuro-2016-0017
doi: 10.1515/revneuro-2016-0017
pubmed: 27508959
Wang G-H, Jiang Z-L, Li Y-C et al (2011) Free-radical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in rats. J Neurotrauma 28:2123–2134. https://doi.org/10.1089/neu.2011.1939
doi: 10.1089/neu.2011.1939
pubmed: 21732763
pmcid: 3191368
Vermersch P, Benrabah R, Schmidt N et al (2012) Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol 12:36. https://doi.org/10.1186/1471-2377-12-36
doi: 10.1186/1471-2377-12-36
pubmed: 22691628
pmcid: 3467179
Mora JS, Genge A, Chio A et al (2020) Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Front Degener 21:5–14. https://doi.org/10.1080/21678421.2019.1632346
doi: 10.1080/21678421.2019.1632346
Dubois B, López-Arrieta J, Lipschitz S et al (2023) Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res Ther 15:39. https://doi.org/10.1186/s13195-023-01169-x
doi: 10.1186/s13195-023-01169-x
pubmed: 36849969
pmcid: 9972756
Li T, Martin E, Abada Y et al (2020) Effects of chronic masitinib treatment in APPswe/PSEN1dE9 transgenic mice modeling Alzheimer’s disease. J Alzheimer’s Dis 76:1339–1345. https://doi.org/10.3233/JAD-200466
doi: 10.3233/JAD-200466
Kocic I, Kowianski P, Rusiecka I et al (2015) Neuroprotective effect of masitinib in rats with postischemic stroke. Naunyn Schmiedebergs Arch Pharmacol 388:79–86. https://doi.org/10.1007/s00210-014-1061-6
doi: 10.1007/s00210-014-1061-6
pubmed: 25344204
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535–b2535. https://doi.org/10.1136/bmj.b2535
doi: 10.1136/bmj.b2535
pubmed: 19622551
pmcid: 2714657
Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8:19–32. https://doi.org/10.1080/1364557032000119616
doi: 10.1080/1364557032000119616
Tricco AC, Lillie E, Zarin W et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467–473. https://doi.org/10.7326/M18-0850
doi: 10.7326/M18-0850
pubmed: 30178033
Hamad AA (2023) Reconsidering the need for de-duplication prior to screening in systematic reviews. AlQ J Med Appl Sci 6:367–368. https://doi.org/10.5281/zenodo.8126972
doi: 10.5281/zenodo.8126972
Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898. https://doi.org/10.1136/bmj.l4898
Sena E, van der Worp HB, Howells D, Macleod M (2007) How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 30:433–439. https://doi.org/10.1016/j.tins.2007.06.009
doi: 10.1016/j.tins.2007.06.009
pubmed: 17765332
Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetic R, Currie M, Lisy K, Qureshi R, Mattis P, Mu P-F (2020) Chapter 7: Systematic reviews of etiology and risk. In: JBI manual for evidence synthesis. JBI. https://doi.org/10.46658/JBIMES-20-08
Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from https://handbook-5-1.cochrane.org/
Piette F, Belmin J, Vincent H et al (2011) Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 3:16. https://doi.org/10.1186/alzrt75
doi: 10.1186/alzrt75
pubmed: 21504563
pmcid: 3226277
Vermersch P, Brieva-Ruiz L, Fox RJ et al (2022) Efficacy and safety of masitinib in progressive forms of multiple sclerosis. Neurol - Neuroimmunol Neuroinflammation 9:e1148. https://doi.org/10.1212/NXI.0000000000001148
doi: 10.1212/NXI.0000000000001148
Mora JS, Bradley WG, Chaverri D et al (2021) Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther Adv Neurol Disord 14:175628642110303. https://doi.org/10.1177/17562864211030365
doi: 10.1177/17562864211030365
Salvado M (2015) Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. World J Gastroenterol 21:10475. https://doi.org/10.3748/wjg.v21.i36.10475
doi: 10.3748/wjg.v21.i36.10475
pubmed: 26420975
pmcid: 4579895
Qian J, Tu H, Zhang D et al (2021) Therapeutic effects of masitinib on abnormal mechanoreception in a mouse model of tourniquet-induced extremity ischemia-reperfusion. Eur J Pharmacol 911:174549. https://doi.org/10.1016/j.ejphar.2021.174549
doi: 10.1016/j.ejphar.2021.174549
pubmed: 34619116
Trias E, Ibarburu S, Barreto-Núñez R et al (2016) Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation 13:177. https://doi.org/10.1186/s12974-016-0620-9
doi: 10.1186/s12974-016-0620-9
pubmed: 27400786
pmcid: 4940876
Trias E, Ibarburu S, Barreto-Núñez R et al (2017) Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight 2. https://doi.org/10.1172/jci.insight.95934
Trias E, King PH, Si Y et al (2018) Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight 3. https://doi.org/10.1172/jci.insight.123249
Trias E, Kovacs M, King PH et al (2020) Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis. Glia 68:1165–1181. https://doi.org/10.1002/glia.23768
Harrison JM, Rafuse VF (2020) Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A mice. Neurobiol Dis 145:105052. https://doi.org/10.1016/j.nbd.2020.105052
doi: 10.1016/j.nbd.2020.105052
pubmed: 32827689
Ehrenreich H, Sirén A-L (2001) Neuroprotection - what does it mean? - what means do we have? Eur Arch Psychiatry Clin Neurosci 251:149–151. https://doi.org/10.1007/s004060170034
doi: 10.1007/s004060170034
pubmed: 11697578
Yang L, Dong Y, Wu C et al (2021) Effects of prenatal photobiomodulation treatment on neonatal hypoxic ischemia in rat offspring. Theranostics 11:1269–1294. https://doi.org/10.7150/thno.49672
doi: 10.7150/thno.49672
pubmed: 33391534
pmcid: 7738878
Soria JC, Massard C, Magné N et al (2009) Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 45:2333–2341. https://doi.org/10.1016/j.ejca.2009.05.010
doi: 10.1016/j.ejca.2009.05.010
pubmed: 19541476
Dubreuil P, Letard S, Ciufolini M et al (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 4:e7258. https://doi.org/10.1371/journal.pone.0007258
doi: 10.1371/journal.pone.0007258
pubmed: 19789626
pmcid: 2746281
Hahn KA, Oglivie G, Rusk T et al (2008) Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 22:1301–1309. https://doi.org/10.1111/j.1939-1676.2008.0190.x
doi: 10.1111/j.1939-1676.2008.0190.x
pubmed: 18823406
Smrkovski OA, Essick L, Rohrbach BW, Legendre AM (2015) Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Vet Comp Oncol 13:314–321. https://doi.org/10.1111/vco.12053
doi: 10.1111/vco.12053
pubmed: 23845124
Adenis A, Blay J-Y, Bui-Nguyen B et al (2014) Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann Oncol 25:1762–1769. https://doi.org/10.1093/annonc/mdu237
doi: 10.1093/annonc/mdu237
pubmed: 25122671
pmcid: 4143095
Deplanque G, Demarchi M, Hebbar M et al (2015) A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol 26:1194–1200. https://doi.org/10.1093/annonc/mdv133
doi: 10.1093/annonc/mdv133
pubmed: 25858497
pmcid: 4516046
Fakhoury M (2015) Role of immunity and inflammation in the pathophysiology of neurodegenerative diseases. Neurodegener Dis 15:63–69. https://doi.org/10.1159/000369933
doi: 10.1159/000369933
pubmed: 25591815
McCauley ME, Baloh RH (2019) Inflammation in ALS/FTD pathogenesis. Acta Neuropathol 137:715–730. https://doi.org/10.1007/s00401-018-1933-9
doi: 10.1007/s00401-018-1933-9
pubmed: 30465257
Calsolaro V, Edison P (2016) Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimer’s Dement 12:719–732. https://doi.org/10.1016/j.jalz.2016.02.010
doi: 10.1016/j.jalz.2016.02.010
Chu F, Shi M, Zheng C et al (2018) The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol 318:1–7. https://doi.org/10.1016/j.jneuroim.2018.02.015
doi: 10.1016/j.jneuroim.2018.02.015
pubmed: 29606295
Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14:463–477. https://doi.org/10.1038/nri3705
doi: 10.1038/nri3705
pubmed: 24962261
El Waly B, Macchi M, Cayre M, Durbec P (2014) Oligodendrogenesis in the normal and pathological central nervous system. Front Neurosci 8. https://doi.org/10.3389/fnins.2014.00145
Kwon HS, Koh S-H (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 9:42. https://doi.org/10.1186/s40035-020-00221-2
Soltani Khaboushan A, Yazdanpanah N, Rezaei N (2022) Neuroinflammation and proinflammatory cytokines in epileptogenesis. Mol Neurobiol 59:1724–1743. https://doi.org/10.1007/s12035-022-02725-6
Woodburn SC, Bollinger JL, Wohleb ES (2021) The semantics of microglia activation: neuroinflammation, homeostasis, and stress. J Neuroinflammation 18:258. https://doi.org/10.1186/s12974-021-02309-6
doi: 10.1186/s12974-021-02309-6
pubmed: 34742308
pmcid: 8571840
Jones MK, Nair A, Gupta M (2019) Mast cells in neurodegenerative disease. Front Cell Neurosci 13. https://doi.org/10.3389/fncel.2019.00171
Teleanu DM, Niculescu A-G, Lungu II et al (2022) An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int J Mol Sci 23:5938. https://doi.org/10.3390/ijms23115938
Ribatti D (2015) The crucial role of mast cells in blood–brain barrier alterations. Exp Cell Res 338:119–125. https://doi.org/10.1016/j.yexcr.2015.05.013
Ettcheto M, Cano A, Sanchez-López E et al (2021) Masitinib for the treatment of Alzheimer’s disease. Neurodegener Dis Manag 11:263–276. https://doi.org/10.2217/nmt-2021-0019
Ketabforoush AHME, Chegini R, Barati S et al (2023) Masitinib: the promising actor in the next season of the amyotrophic lateral sclerosis treatment series. Biomed Pharmacother 160:114378. https://doi.org/10.1016/j.biopha.2023.114378
doi: 10.1016/j.biopha.2023.114378
pubmed: 36774721